Bimetal iridium complex conjugate, preparation method and application in thrombolysis

By designing the bimetallic iridium complex conjugate CuIr to form nanoparticle CuIr NPs, the shortcomings of existing photodynamic therapy and photothermal therapy in thrombolysis therapy are solved, and efficient bioluminescence and photothermal synchronization at the thrombus location are achieved. Treatment overcomes the problem of limited light penetration depth and significantly improves the effect of thrombolysis treatment.

CN118878587AActive Publication Date: 2024-11-01SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Patent Information

Application Number
CN202410884248.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-03
Publication Date
2024-11-01
Estimated Expiration
2044-07-03

AI Technical Summary

Technical Problem

The existing photodynamic therapy and photothermal therapy have low selectivity, short half-life, high risk of bleeding, oxygen dependence, insufficient production efficiency of photosensitizer ROS and insufficient light source wavelength in thrombolysis therapy, which limits its clinical application. Moreover, the iridium complex suitable for PTT and PDT is limited and difficult to design against the thrombotic microenvironment.

Method used

A bimetallic iridium complex conjugate CuIr was designed to form nanoparticle CuIr NPs by synthesizing paths IrCl3·3H2O and phenylpyridine ligand, porphyrin Schiff base ligand and copper acetate, which has chemiluminescent properties and can React with the thrombosis inflammation location without the need for an external excitation light source, producing bioluminescence, overcoming the problem of limited light penetration depth.

Benefits of technology

CuIr NPs show excellent bioluminescence performance, can specifically identify the position of the plug block, have a high penetration of 12mm, realize the effect of photodynamic photothermal synergistic treatment, improve the efficiency and safety of thrombolysis treatment, and have good Photodynamic photothermal ability indicates effective treatment of thrombosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118878587A_ABST
    Figure CN118878587A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of photodynamic therapy drugs, and particularly relates to a bimetallic iridium complex conjugate, a preparation method and application in thrombolysis. The structural formula of the bimetallic iridium complex conjugate is shown as follows: # imgabs0 #, and Cu metal is introduced, so that the metal iridium complex has a chemiluminescence property, and the treatment effect of photo-thermal and photodynamic synergistic treatment can be simultaneously realized. The bimetallic CuIr NPs provided by the invention has good photodynamic photo-thermal capability, and can overcome the problems of short excitation wavelength of exciting light and limited light penetration depth required by the existing metal iridium complex. Experiments show that the material has a good treatment effect on thrombus, and is expected to be developed as a phototherapy material and used as a thrombolysis photosensitizer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of photodynamic therapy drugs, and specifically relates to a bimetallic iridium complex conjugate, a preparation method and an application in thrombolysis. Technical Background

[0002] Phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), is an emerging, non-invasive, real-time controllable light stimulation method with broad application prospects in the field of disease treatment. Compared with traditional drugs and surgery, phototherapy has inherent advantages such as non-invasiveness, low toxicity, simple operation, and fast recovery, and has attracted much attention in the medical field.

[0003] Surgical removal of emboli or drug thrombolysis are the main methods for clinical treatment of thrombotic diseases. However, current thrombolytic drugs often show only limited therapeutic effects due to their low selectivity, short half-life and non-negligible bleeding risk. In recent years, the non-invasive application of photosensitizers in the diagnosis and treatment of cardiovascular and cerebrovascular diseases has attracted widespread attention, especially in the field of thrombolysis, and has the potential to become a new generation of treatment methods.

[0004] Although PTT has shown some potential in thrombolytic therapy, the nonspecific thermal damage of PTT to nearby tissues is a problem that limits its application. In addition, high cost, insufficient photothermal effect, low biodegradability and possible toxicity also limit the clinical transformation of PTT in thrombolytic therapy. PDT has been used in thrombolytic therapy research due to its advantages such as rapid onset, mild adverse reactions, and can be used in combination with other therapies. However, the clinical application of PDT is also limited by its dependence on oxygen, insufficient ROS generation efficiency of photosensitizers, and like PTT, there is a problem of limited penetration depth due to insufficient wavelength of the light source.

[0005] As research deepens, the integration of PTT and PDT into a single system for synergistic treatment shows a promising prospect of high efficiency and safety. The oxygen independence of PTT can make up for the oxygen dependence of PDT. At the same time, the local thermal effect of PTT can accelerate local blood circulation and increase local oxygen supply, promoting local PDT.

[0006] Transition metal materials are favored for their rich excited state properties, such as high luminescence quantum efficiency, ultra-long luminescence lifetime, high stability luminescence, and multicolor luminescence. Compared with other transition metal complexes, cyclometallated iridium complexes have long triplet excitation lifetimes, large Stokes shifts, and outstanding photothermal generation capabilities, and are currently the most widely used type of transition metal complex materials. In 2020, Professor Gou Shaohua's team at Southeast University rationally designed a metal iridium complex with a donor-acceptor-donor (DAD) based on a simple skeleton structure for the first time, and used the synergistic effect of photodynamics and photothermal to achieve efficient anti-thrombotic therapeutic effects. However, the synthesis of this photosensitizer is relatively complex, which limits its wide application. (AnIridium(III) Complex Bearing a Donor–Acceptor–Donor Type Ligand for NIR-Triggered Dual Phototherapy[J]. Advanced Functional Materials, 2020.). In 2021, the inventors rationally designed single-core and quadruple-core metal iridium complexes based on the skeleton structure of porphyrin and achieved excellent photothermal performance, but the fluorescent photosensitizer will affect the imaging effect due to its own background (Zhang Liping. Design, synthesis and phototherapy application research of deep red / near-infrared light photosensitizers based on metal iridium complexes and organic small molecules [D]. Northeast Normal University, 2021.).

[0007] At present, iridium complexes suitable for integrated PTT and PDT therapy are still limited, and there are few reports on drug design targeting the thrombus microenvironment. Providing more iridium complexes that can be used for integrated therapy is of great significance for the clinical selection of thrombolytic therapy. Summary of the invention

[0008] In order to solve the above problems, one of the purposes of the present invention is to provide a bimetallic iridium complex conjugate, the structural formula of the bimetallic iridium complex conjugate is shown in formula (I):

[0009]

[0010] The second object of the present invention is to provide a method for preparing the bimetallic iridium complex conjugate as described above, comprising the following steps:

[0011] S1. Under nitrogen protection, IrCl 3 ·3H 2 O and phenylpyridine ligand were heated under reflux to obtain phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 ;

[0012] S2. Under nitrogen protection, the phenylpyridine iridium dichloro bridge and the porphyrin Schiff base ligand are placed in a dark place under the action of a solvent for reflux reaction. After the reaction is completed, potassium hexafluorophosphate is added at a molar ratio of 1:5 to the phenylpyridine iridium dichloro bridge and continued to stir to obtain a binuclear metal iridium complex 2Ir;

[0013] S3. Under nitrogen protection, the binuclear iridium complex 2Ir was mixed with copper acetate, 15 mL 0.1 mmol DMF was added as a reaction solvent, and the mixture was stirred at 80° C. for 8 h to react to obtain a bimetallic iridium complex conjugate CuIr.

[0014] Preferably, in step S1, the IrCl 3 ·3H 2 The molar ratio of O to the phenylpyridine ligand is 1:(2.5-3).

[0015] Preferably, the solvent is 2-ethylene glycol ethyl ether.

[0016] Preferably, in step S1, the temperature of the reflux reaction is 120-130° C., and the time of the reflux reaction is 24-30 h.

[0017] Preferably, in step S2, the molar ratio of the phenylpyridine iridium dichloro bridge to the porphyrin Schiff base ligand is 1:1.

[0018] Preferably, in step S2, the temperature of the reflux reaction is 75-80° C., and the time of the reflux reaction is 8 h.

[0019] Preferably, in step S2, the solvent is dichloromethane and methanol (v:v=1:1).

[0020] Preferably, in step S3, the molar ratio of 2Ir to copper acetate is 1:(3-5).

[0021] The synthetic route of the preparation method is shown as follows:

[0022]

[0023]

[0024] S1. Add IrCl to a reaction vessel containing solvent and water in a molar ratio of 1:(2.5-3). 3 ·3H 2 O and phenylpyridine ligand, and heated to reflux reaction under nitrogen protection, reflux reaction at 120-130°C for 24-30h, and then add a large amount of poor solvent water to precipitate the precipitate and filter it, and rinse the solvent with a large amount of water and ethanol. The obtained solid is dried to obtain phenylpyridine iridium dichloro bridge [Ir(ppy)2 Cl 2 ] 2 (L2);

[0025] The solvent in the reaction vessel is preferably 2-ethylene glycol ethyl ether.

[0026] S2. In a molar ratio of 1:1, add the phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 and porphyrin Schiff base ligand, then add a solvent, the solvent is dichloromethane and methanol (v:v=1:1), and fill with inert gas N 2 When the reaction is completed and cooled to room temperature, solid potassium hexafluorophosphate is added to the solution in the bottle, and stirring is continued at room temperature for 45 to 60 minutes. The solvent in the system is removed by a rotary evaporator, and then extracted with dichloromethane and water to remove excess solid potassium hexafluorophosphate. The obtained substance is washed with petroleum ether and dried, and purified by column chromatography to obtain a purple-red solid, namely 2Ir.

[0027] S3. Under nitrogen protection, 2Ir prepared in step S2 is mixed with copper acetate in a molar ratio of 1:(3-5), DMF is added as a reaction solvent, and the mixture is stirred at 80°C for 8h to react. The obtained product is extracted with dichloromethane and water, and the solvent in the system is removed by a rotary evaporator. The product is dried to obtain a red solid product, i.e., a bimetallic iridium complex conjugate CuIr.

[0028] The above-mentioned preparation routes are mainly for explaining the present invention rather than limiting it.

[0029] The third object of the present invention is to provide a nanoparticle, which is prepared by using the bimetallic iridium complex conjugate as described above, and the particle size of the nanoparticle is 100-200nm.

[0030] The fourth object of the present invention is to provide a method for preparing the nanoparticles as described above, the method comprising: dissolving CuIr and distearoylphosphatidylethanolamine-polyethylene glycol in tetrahydrofuran respectively, adding dropwise into water, stirring and volatilizing for 24 hours at room temperature, and then dialyzing using a 2000 molecular weight dialysis membrane to obtain CuIr NPs with uniform particle size and stability.

[0031] A fifth object of the present invention is to provide the use of the bimetallic iridium complex conjugate as described above or the nanoparticle as described above as a phototherapy material.

[0032] Preferably, the phototherapeutic material is a photoinitiator.

[0033] A sixth object of the present invention is to provide the use of the bimetallic iridium complex conjugate as described above or the nanoparticles as described above in the preparation of thrombolytic drugs.

[0034] Preferably, the thrombolytic drug is a drug for treating thrombosis.

[0035] The beneficial effects of the present invention are:

[0036] The present invention designs and synthesizes a bimetallic iridium complex conjugate CuIr in a simple and convenient way. By introducing Cu metal, the metal iridium complex has the property of chemiluminescence, so that it can simultaneously achieve the therapeutic effects of photothermal and photodynamic synergistic therapy.

[0037] The invention also provides nanoparticles CuIr NPs formed by biologically encapsulating the bimetallic iridium complex conjugate CuIr into the amphiphilic polymer distearoylphosphatidylethanolamine-polyethylene glycol. The CuIr NPs have excellent bioluminescent properties and can specifically identify the location of the plug.

[0038] The CuIr NPs provided by the present invention can react chemically with excess ROS at the thrombus inflammation site without the need for an external excitation light source to produce bioluminescence. Experiments show that it has a high penetration of 12 mm, which can overcome the problem of short excitation wavelength and limited light penetration depth required by the existing metal iridium complex itself. The test results show that CuIrNPs have good photodynamic and photothermal capabilities, which indicates that the material has a good therapeutic effect on thrombus and is expected to be developed as a phototherapy material and used as a thrombolytic photosensitizer. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 Mass spectrometry data of CuIr NPs prepared in Example 1 of the present invention.

[0040] Figure 2 This is a particle size potential diagram of CuIr NPs prepared in Example 1 of the present invention, where A, B, and C correspond to the particle sizes of TPP NPs, 2Ir NPs, and CuIr NPs, respectively; and D is the potential of TPP NPs, 2Ir NPs, and CuIr NPs.

[0041] Figure 3 The ultraviolet absorption spectra (A in the figure) and fluorescence emission spectra (B in the figure) of CuIr NPs, 2Ir NPs and TPP NPs prepared in Example 1 of the present invention in aqueous solution.

[0042] Figure 4This is a diagram of ROS generation in aqueous solution of CuIr NPs (A in the figure), 2Ir NPs (B in the figure), and TPP NPs (C in the figure) prepared in Example 1 of the present invention with DPBF.

[0043] Figure 5 The first-order kinetic curves of CuIr NPs, 2Ir NPs and TPP NPs prepared in Example 1 of the present invention in aqueous solution (B in the figure is the logarithmic curve of A), the larger the slope, the more singlet oxygen is produced.

[0044] Figure 6 These are the photothermal data diagrams of CuIr NPs, 2Ir NPs, and TPP NPs prepared in Example 1 of the present invention in aqueous solution, wherein A is the control group, B is the temperature change at different concentrations, C is the temperature change at different powers, and D is the photothermal cycle of the drug.

[0045] Figure 7 This is a thermal imaging data diagram of CuIr NPs prepared in Example 1 of the present invention in an aqueous solution.

[0046] Figure 8 This is a graph of the chemiluminescent properties of CuIr NPs prepared in Example 1 of the present invention, in which A is a selectivity intensity graph of different ROS, B is the chemiluminescence intensity at different times, C is the chemiluminescence intensity at different nm, D shows the concentration-dependent results, and E is the chemiluminescence penetration imaging under chicken breast coverage of different thicknesses.

[0047] Fig. 9 This is an in vitro targeting test diagram of CuIr NPs prepared in Example 1 of the present invention.

[0048] Fig.10 This is a test diagram of the antioxidant capacity of CuIr NPs prepared in Example 1 of the present invention, where A is the total antioxidant capacity test and B is the hydrogen peroxide consumption.

[0049] Fig.11 This is a hemolysis test diagram of CuIr NPs prepared in Example 1 of the present invention.

[0050] Fig.12 This is a graph showing the thrombolysis data of CuIr NPs prepared in Example 1 of the present invention under different conditions.

[0051] Fig.13 This is a photothermal imaging image of the thrombus location in mice using CuIr NPs prepared in Example 1 of the present invention.

[0052] Fig.14 This is a chemiluminescent imaging image of the thrombus location in mice using CuIr NPs prepared in Example 1 of the present invention.

[0053] Fig.15This is a diagram of thrombolysis in mice of CuIr NPs prepared in Example 1 of the present invention.

[0054] Fig.16 This is the laser speckle pattern of CuIr NPs prepared in Example 1 of the present invention in mice. DETAILED DESCRIPTION

[0055] Unless otherwise specified, the terms used herein have the meanings commonly understood by those skilled in the art.

[0056] The technical solution of the present invention is described in more detail below in conjunction with the embodiments:

[0057] Example 1

[0058] Bimetallic iridium complex conjugate CuIr, the structural formula is shown in Formula Ⅰ:

[0059]

[0060] The preparation method of the above-mentioned bimetallic iridium complex conjugate is:

[0061] S1. Add IrCl to a round-bottom flask containing 30 mL of 2-ethylene glycol ether and 10 mL of water. 3 ·3H 2 O (0.1 mmol, 0.0352 g) and phenylpyridine ligand (0.3 mmol, 0.0471 g) were reacted in N 2 Under a protective atmosphere, the reaction was heated at 120°C for 24 hours under reflux. After the reaction was cooled to room temperature, a large amount of poor solvent water was added to precipitate the precipitate, which was filtered and washed several times with a large amount of water and ethanol solvent. The solid obtained by drying was phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 .

[0062] S2. Add the phenylpyridine iridium dichlorobridge [Ir(ppy) 2 Cl 2 ] 2 (0.1mmol, 0.1072g) 1 and porphyrin Schiff base (0.1mmol, 0.0822g), then add 60mL of dichloromethane and methanol (v:v=1:1) as the solvent of the reaction system. 2When the reaction is completed and cooled to room temperature, 10 equivalents of solid potassium hexafluorophosphate are added to the solution in the bottle, and stirring is continued at room temperature for 45 minutes. The solvent in the system is removed by a rotary evaporator, and the excess solid potassium hexafluorophosphate is removed by extraction with dichloromethane and water. The obtained substance is washed with petroleum ether and dried, and purified by column chromatography to obtain a purple-red solid, namely 2Ir.

[0063] S3. Add 2Ir (0.1mmol, 0.1824g) and copper acetate (0.5mmol, 0.0998g) to a 100mL beaker, use DMF as the reaction solvent, stir and react at 80℃ for 8h, extract the product with dichloromethane and water, remove the solvent in the system by rotary evaporator, and dry to obtain a red solid product, i.e., bimetallic iridium complex conjugate CuIr, with a yield of 90%, and the molecular formula is C 36 H 22 Ir 4 Na 2 O 4 , the relative molecular mass is 1885.42g / mol. Figure 1 The mass spectrometry data of the prepared CuIr shows a molecular weight of 942.43 g / mol, which is the same as the fitted molecular weight (CuIr has two charges and the molecular ion peak is 1 / 2 of the total mass), which can prove the structure.

[0064] Example 2

[0065] S1. Add IrCl to a round-bottom flask containing 30 mL of 2-ethylene glycol ether and 10 mL of water. 3 ·3H 2 O (0.1 mmol, 0.0352 g) and phenylpyridine ligand (0.25 mmol, 0.0392 g) were reacted in N 2 Under a protective atmosphere, the reaction was heated at 120°C for 24 hours under reflux. After the reaction was cooled to room temperature, a large amount of poor solvent water was added to precipitate the precipitate, which was filtered and washed several times with a large amount of water and ethanol solvent. The solid obtained by drying was phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 .

[0066] S2. Add the phenylpyridine iridium dichlorobridge [Ir(ppy) 2 Cl 2 ] 2(0.1mmol, 0.1072g) 1 and porphyrin Schiff base (0.1mmol, 0.0822g), then add 60mL of dichloromethane and methanol (v:v=1:1) as the solvent of the reaction system. 2 When the reaction is completed and cooled to room temperature, 10 equivalents of solid potassium hexafluorophosphate are added to the solution in the bottle, and stirring is continued at room temperature for 45 minutes. The solvent in the system is removed by a rotary evaporator, and the excess solid potassium hexafluorophosphate is removed by extraction with dichloromethane and water. The obtained substance is washed with petroleum ether and dried, and purified by column chromatography to obtain a purple-red solid, namely 2Ir.

[0067] S3. Add 2Ir (0.1mmol, 0.1824g) and copper acetate (0.5mmol, 0.0998g) to a 100mL beaker, use DMF as the reaction solvent, stir and react at 80℃ for 8h, extract the product with dichloromethane and water, remove the solvent in the system by rotary evaporator, and dry to obtain a red solid product, i.e., bimetallic iridium complex conjugate CuIr, with a yield of 85%, and a molecular formula of C 36 H 22 Ir 4 Na 2 O 4 , the relative molecular mass is 1885.42g / mol.

[0068] Example 3

[0069] S1. Add IrCl to a round-bottom flask containing 30 mL of 2-ethylene glycol ether and 10 mL of water. 3 ·3H 2 O (0.1 mmol, 0.0352 g) and phenylpyridine ligand (0.3 mmol, 0.0471 g) were reacted in N 2 Under a protective atmosphere, the reaction was heated at 120°C for 30 hours under reflux. After the reaction was cooled to room temperature, a large amount of poor solvent water was added to precipitate the precipitate, which was filtered and washed several times with a large amount of water and ethanol solvent. The solid obtained by drying was phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 .

[0070] S2. Add the phenylpyridine iridium dichlorobridge [Ir(ppy) 2 Cl 2 ] 2(0.1mmol, 0.1072g) 1 and porphyrin Schiff base (0.1mmol, 0.0822g), then add 60mL of dichloromethane and methanol (v:v=1:1) as the solvent of the reaction system. 2 When the reaction is completed and cooled to room temperature, 10 equivalents of solid potassium hexafluorophosphate are added to the solution in the bottle, and stirring is continued at room temperature for 45 minutes. The solvent in the system is removed by a rotary evaporator, and the excess solid potassium hexafluorophosphate is removed by extraction with dichloromethane and water. The obtained substance is washed with petroleum ether and dried, and purified by column chromatography to obtain a purple-red solid, namely 2Ir.

[0071] S3. Add 2Ir (0.1mmol, 0.1824g) and copper acetate (0.5mmol, 0.0998g) to a 100mL beaker, use DMF as the reaction solvent, stir and react at 80℃ for 8h, extract the product with dichloromethane and water, remove the solvent in the system by rotary evaporator, and dry to obtain a red solid product, i.e., bimetallic iridium complex conjugate CuIr, with a yield of 93% and a molecular formula of C 36 H 22 Ir 4 Na 2 O 4 , the relative molecular mass is 1885.42g / mol.

[0072] Example 4

[0073] S1. Add IrCl to a round-bottom flask containing 30 mL of 2-ethylene glycol ether and 10 mL of water. 3 ·3H 2 O (0.1 mmol, 0.0352 g) and phenylpyridine ligand (0.3 mmol, 0.0471 g) were reacted in N 2 Under a protective atmosphere, the reaction was heated at 130°C for 24 hours under reflux. After the reaction was cooled to room temperature, a large amount of poor solvent water was added to precipitate the precipitate, which was filtered and washed several times with a large amount of water and ethanol solvent. The solid obtained by drying was phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 .

[0074] S2. Add the phenylpyridine iridium dichlorobridge [Ir(ppy) 2 Cl 2 ] 2(0.1mmol, 0.1072g) 1 and porphyrin Schiff base (0.1mmol, 0.0822g), then add 60mL of dichloromethane and methanol (v:v=1:1) as the solvent of the reaction system. 2 When the reaction is completed and cooled to room temperature, 10 equivalents of solid potassium hexafluorophosphate are added to the solution in the bottle, and stirring is continued at room temperature for 45 minutes. The solvent in the system is removed by a rotary evaporator, and the excess solid potassium hexafluorophosphate is removed by extraction with dichloromethane and water. The obtained substance is washed with petroleum ether and dried, and purified by column chromatography to obtain a purple-red solid, namely 2Ir.

[0075] S3. Add 2Ir (0.1mmol, 0.1824g) and copper acetate (0.5mmol, 0.0998g) to a 100mL beaker, use DMF as the reaction solvent, stir and react at 80℃ for 8h, extract the product with dichloromethane and water, remove the solvent in the system by rotary evaporator, and dry to obtain a red solid product, i.e., bimetallic iridium complex conjugate CuIr, with a yield of 91% and a molecular formula of C 36 H 22 Ir 4 Na 2 O 4 , the relative molecular mass is 1885.42g / mol.

[0076] Example 5

[0077] S1. Add IrCl to a round-bottom flask containing 30 mL of 2-ethylene glycol ether and 10 mL of water. 3 ·3H 2 O (0.1 mmol, 0.0352 g) and phenylpyridine ligand (0.3 mmol, 0.0471 g) were reacted in N 2 Under a protective atmosphere, the reaction was heated at 120°C for 24 hours under reflux. After the reaction was cooled to room temperature, a large amount of poor solvent water was added to precipitate the precipitate, which was filtered and washed several times with a large amount of water and ethanol solvent. The solid obtained by drying was phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 .

[0078] S2. Add the phenylpyridine iridium dichlorobridge [Ir(ppy) 2 Cl 2 ] 2(0.1mmol, 0.1072g) 1 and porphyrin Schiff base (0.1mmol, 0.0822g), then add 60mL of dichloromethane and methanol (v:v=1:1) as the solvent of the reaction system. 2 When the reaction is completed and cooled to room temperature, 10 equivalents of solid potassium hexafluorophosphate are added to the solution in the bottle, and stirring is continued at room temperature for 45 minutes. The solvent in the system is removed by a rotary evaporator, and the excess solid potassium hexafluorophosphate is removed by extraction with dichloromethane and water. The obtained substance is washed with petroleum ether and dried, and purified by column chromatography to obtain a purple-red solid, namely 2Ir.

[0079] S3. Add 2Ir (0.1mmol, 0.1824g) and copper acetate (0.3mmol, 0.0599g) to a 100mL beaker, use DMF as the reaction solvent, stir and react at 80℃ for 8h, extract the product with dichloromethane and water, remove the solvent in the system by rotary evaporator, and dry to obtain a red solid product, i.e., bimetallic iridium complex conjugate CuIr, with a yield of 88% and a molecular formula of C 36 H 22 Ir 4 Na 2 O 4 , the relative molecular mass is 1885.42g / mol.

[0080] Example 6

[0081] S1. Add IrCl to a round-bottom flask containing 30 mL of 2-ethylene glycol ether and 10 mL of water. 3 ·3H 2 O (0.1 mmol, 0.0352 g) and phenylpyridine ligand (0.3 mmol, 0.0471 g) were reacted in N 2 Under a protective atmosphere, the reaction was heated at 120°C for 24 hours under reflux. After the reaction was cooled to room temperature, a large amount of poor solvent water was added to precipitate the precipitate, which was filtered and washed several times with a large amount of water and ethanol solvent. The solid obtained by drying was phenylpyridine iridium dichloro bridge [Ir(ppy) 2 Cl 2 ] 2 .

[0082] S2. Add the phenylpyridine iridium dichlorobridge [Ir(ppy) 2 Cl 2 ] 2(0.1mmol, 0.1072g) 1 and porphyrin Schiff base (0.1mmol, 0.0822g), then add 60mL of dichloromethane and methanol (v:v=1:1) as the solvent of the reaction system. 2 When the reaction is completed and cooled to room temperature, 10 equivalents of solid potassium hexafluorophosphate are added to the solution in the bottle, and stirring is continued at room temperature for 45 minutes. The solvent in the system is removed by a rotary evaporator, and the excess solid potassium hexafluorophosphate is removed by extraction with dichloromethane and water. The obtained substance is washed with petroleum ether and dried, and purified by column chromatography to obtain a purple-red solid, namely 2Ir.

[0083] S3. Add 2Ir (0.1mmol, 0.1824g) and copper acetate (0.4mmol, 0.080g) to a 100mL beaker, use DMF as the reaction solvent, stir and react at 77°C for 8h, extract the product with dichloromethane and water, remove the solvent in the system by rotary evaporator, and dry to obtain a red solid product, i.e., bimetallic iridium complex conjugate CuIr, with a yield of 86% and a molecular formula of C 36 H 22 Ir 4 Na 2 O 4 , the relative molecular mass is 1885.42g / mol.

[0084] experiment

[0085] The performance of the bimetallic iridium complex conjugate CuIr prepared in Example 1 was characterized as follows:

[0086] 1. Preparation of Nanoparticles

[0087] CuIr (0.0010 g, prepared in Example 1) and distearoylphosphatidylethanolamine-polyethylene glycol (0.0020 g) were dissolved in 1 ml of tetrahydrofuran, respectively, and the two were added dropwise to the prepared 10 mL of water, stirred and evaporated overnight at room temperature. After the end, dialyzed using a 2000 molecular weight dialysis membrane to obtain CuIr NPs with uniform particle size and stability.

[0088] 2Ir (0.0010 g) and distearoylphosphatidylethanolamine-polyethylene glycol (0.0020 g) were dissolved in 1 ml of tetrahydrofuran respectively, and then added dropwise to the prepared 10 mL of water. The mixture was stirred and evaporated overnight at room temperature. After evaporation, a 2000 molecular weight dialysis membrane was used for dialysis to obtain 2IrNPs nanoparticles with uniform particle size and stable dispersion in aqueous solution.

[0089] TPP (0.0010 g) and distearoylphosphatidylethanolamine-polyethylene glycol (0.0020 g) were dissolved in 1 ml of tetrahydrofuran respectively, and then added dropwise to the prepared 10 mL of water. The mixture was stirred and evaporated overnight at room temperature. After the mixture was evaporated, it was dialyzed using a 1000 molecular weight dialysis membrane to obtain TPPNPs nanoparticles with uniform particle size and stable dispersion in aqueous solution.

[0090] 2. Physical properties of CuIr NPs

[0091] Figure 2 The particle size and potential diagram of TPP NPs, 2Ir NPs, and CuIr NPs (measured by particle size potential analyzer). It can be seen from the figure that the particle sizes of TPP NPs, 2Ir NPs, and CuIr NPs in aqueous solution are 75.91nm, 92.66nm, and 129nm, respectively. At the same time, the potential of CuIr NPs was measured to be -25mV.

[0092] The uniform particle size of <200 nm indicates that CuIr has good biocompatibility and a negative potential, indicating that it can have a good circulation effect in the body.

[0093] 3. Photophysical properties of CuIr NPs

[0094] The UV absorption and fluorescence emission of CuIr NPs in aqueous solution were measured by UV-visible spectrophotometer and fluorescence spectrometer. Figure 3 As shown in the figure, the absorption in the ultraviolet absorption disappears because the Cu metal enters the porphyrin core, and the emission intensity becomes weaker due to the introduction of the Ir core. When Cu is introduced, the fluorescence is quenched.

[0095] Figure 4 , Figure 5 For the CuIr NPs prepared in the present invention, an in vitro singlet oxygen generation experiment and a related kinetic curve under the conditions of light and DPBF were measured by an ultraviolet spectrophotometer. The degradation of DPBF under light proved that the CuIr NPs had a good singlet oxygen generation ability.

[0096] 4. Photothermal properties of CuIr NPs

[0097] Thermocouple photothermal data, Figure 6 A shows the difference between the control group and H 2 O, drug group (TPP NPs, 2Ir NPs, CuIr NPs) has better photothermal generation ability; Figure 6 Middle B shows that the higher the concentration of CuIr NPs, the higher the temperature under the same illumination time, indicating that it is concentration-dependent; Figure 6Middle C shows that the heat generation and temperature rise of CuIr NPs at different powers are higher with higher power, indicating that it is power-dependent; Figure 6 D in the middle shows the temperature change of CuIr NPs after five heating and cooling cycles, which shows that the drug has good photothermal cycling ability.

[0098] Figure 7 This is the thermal imaging image of CuIr NPs corresponding to the photothermal data. Under illumination conditions, the solution temperature increases with the extension of illumination time.

[0099] 5. Chemiluminescence experiment of CuIr NPs

[0100] Figure 8 The relevant data table of CuIr NPs chemiluminescence is shown in the figure below. The relevant chemiluminescence test was performed using IVIS mouse in vivo imaging system. Figure 8 A, Different types of RONS were co-incubated with CuIrNPs in a 96-well plate in response to different ROS, ONOO - The luminescence intensity was the strongest. - As a marker substance, it can respond to CuIr NPs to produce chemiluminescence, illuminating the inflammatory site. Figure 8 In Figure B, at different illumination times, the test results show that the drug luminescence intensity is highest when the illumination is 90s, and this time is selected as the illumination time for in vivo drug imaging. Figure 8 In C, the dotted line graph of chemiluminescence intensity at different nanometers shows that the drug has the highest intensity of bioluminescence emission at 800nm. Figure 8 Middle D, different proportions of ONOO - The results of coexistence measurements with the drug showed a linear correlation. Figure 8 In Figure E, chicken breasts of different thicknesses are used to cover the drug, and the chemiluminescence can penetrate up to 12 mm. The high penetration depth is conducive to imaging tests of drugs at deep inflammatory sites. This has significant advantages over photosensitizers that rely on short-wavelength excitation light.

[0101] Fig. 9 This is an in vitro targeting test of the CuIr NPs of the present invention. Fresh mouse blood was added to a 5 mL test tube without anticoagulant and refrigerated at 4°C for 24 hours to obtain a thrombus. The drug was co-incubated with the thrombus, and the chemiluminescence intensity was detected at 2 hours, 4 hours, and 6 hours. The results showed that the longer the co-incubation time with the drug, the higher the chemiluminescence intensity, which proved that the drug had a good targeting ability for the thrombus.

[0102] 6. Antioxidant performance experiment of CuIr NPs

[0103] Fig.10The test results of the antioxidant capacity of CuIr NPs. Fig.10 Figure A, using the kit for testing, shows that when the concentration of CuIr NPs reaches 300μg / mL, the consumption rate of DPPH can reach 70%. Fig.10 In panel B, co-incubation with hydrogen peroxide detected a consumption rate of nearly 60%.

[0104] At the site of the thrombus, the hydrogen peroxide content is far higher than that of normal tissue. The consumption of hydrogen peroxide will effectively improve the microenvironment at the site of the thrombus. At the same time, it proves that CuIr NPs have good antioxidant capacity, showing that it has a good therapeutic effect on inflammation in the body.

[0105] 7. Hemolysis experiment of CuIr NPs

[0106] Fig.11 This is the hemolysis test of CuIr NPs. Different concentrations of CuIr NPs were incubated with red blood cells in hot water at 37°C for 2 hours. The PBS group was the negative control group and the water group was the positive control group. The hemolysis rate of the drug was still less than 5% at 200 μg / mL, indicating that it has good biosafety.

[0107] 8. In vitro thrombolysis experiment of CuIr NPs

[0108] 5 mL of NPs from different groups and thrombus were placed in 10 mL vials for in vitro thrombolysis test. Fig.12 As shown. Compared with the control group, the CuIr NPs group can simultaneously open PDT / PTT dual-mode thrombolysis under laser irradiation, and the thrombolysis rate reached 68.7%. In the study, PDT and PTT were also demonstrated during thrombolysis. The results showed that the thrombolysis rate was 34.7% only during PTT, which was higher than the thrombolysis efficiency of PDT performed at low temperature. The experimental results show that CuIr NPs has good in vitro thrombolysis ability.

[0109] 9. In vivo experiments on CuIr NPs in mice

[0110] Fig.13 The in vivo photothermal imaging test results of CuIr NPs. The mice were anesthetized and the right carotid artery was found. 3 After about 10 minutes of solution, the blood vessels turned black and thrombus formation was completed. After tail vein administration, the drug circulated to the thrombus location to form a thrombus. An infrared thermal imager was used to record the temperature of the thrombus location as the drug accumulated at the thrombus location and the illumination time increased. The results showed that the temperature of the thrombus location gradually increased with the extension of illumination time.

[0111] Fig.14This is the in vivo chemiluminescence imaging of CuIr NPs. It can be seen that after the tail vein administration, as time goes by, the drug circulates to the location of the thrombus, the chemiluminescence phenomenon is obvious under light, and the aggregation degree reaches the maximum at 60 minutes, and thrombolytic therapy can be started.

[0112] Fig.15 Figure 1 shows the in vivo thrombolytic test of CuIr NPs. The mouse was anesthetized, the thoracotomy was performed, and the right carotid artery was found and incubated with 10% FeCl 3 The solution lasted for about 10 minutes, the blood vessels turned black, and the thrombus formation was completed. After the drug was administered, it circulated to the thrombus position. The laser (635nm 0.8w / cm 2 ) irradiated the thrombus location, and the thrombolysis rate in the body reached 72%, which had a good thrombolytic effect.

[0113] Fig.16 This is a record of blood flow during the laser speckle monitoring thrombolysis process of CuIr NPs. After the formation of thrombus in vivo, the thrombolysis rate of the CuIr NPs group gradually dissolves the thrombus as the light treatment time prolongs, and the blood flow gradually recovers. Unlike the common thrombolytic drug UK enzyme, which may cause secondary embolism after thrombus clearance, resulting in a decrease in blood flow, the CuIr NPs-treated group did not experience re-embolism during thrombolysis, proving that the good PDT / PTT ability of CuIr NPs can effectively prevent re-embolism and perform well in in vivo treatment.

[0114] The above implementation modes are only used to illustrate the technical solutions of the present invention, but not to limit the present invention. Although the present invention has been described in detail with reference to the above implementation modes, those skilled in the art should understand that any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A bimetallic iridium complex conjugate, characterized in that: The structural formula is shown in formula (I):

2. A method for preparing a bimetallic iridium complex conjugate as claimed in claim 1, characterized in that: The following steps are involved: S1. Under nitrogen protection, IrCl3·3H2O and phenylpyridine ligand are heated to reflux to obtain phenylpyridine iridium dichloro bridge; S2. Under nitrogen protection, the phenylpyridine iridium dichloro bridge and the porphyrin Schiff base ligand are placed in a dark place under the action of a solvent for reflux reaction. After the reaction is completed, potassium hexafluorophosphate is added at a molar ratio of 1:5 to the phenylpyridine iridium dichloro bridge and continued to stir to obtain a binuclear metal iridium complex 2Ir; S3. Under nitrogen protection, the binuclear metal iridium complex 2Ir was mixed with copper acetate, 15 mL 0.1 mmol DMF was added as a reaction solvent, and the mixture was stirred at 80° C. for 8 h to react to obtain a bimetallic iridium complex conjugate.

3. The method for preparing a bimetallic iridium complex conjugate according to claim 2, characterized in that: In step S1, the molar ratio of IrCl3·3H2O to phenylpyridine ligand is 1:(2.5-3), and the solvent is 2-ethylene glycol ethyl ether.

4. The method for preparing a bimetallic iridium complex conjugate according to claim 2, characterized in that: In step S1, the temperature of the reflux reaction is 120-130° C., and the time of the reflux reaction is 24-30 hours.

5. The method for preparing a bimetallic iridium complex conjugate according to claim 2, characterized in that: In step S2, the molar ratio of the phenylpyridine iridium dichloro bridge and the porphyrin Schiff base ligand is 1:1, the solvent is prepared by mixing dichloromethane and methanol in a volume ratio of 1:1, the temperature of the reflux reaction is 75-80° C., and the reflux reaction time is 8 hours.

6. The method for preparing a bimetallic iridium complex conjugate according to claim 2, characterized in that: In step S3, the molar ratio of 2Ir to copper acetate is 1:(3-5).

7. A nanoparticle, characterized in that: The nanoparticles are prepared by using the bimetallic iridium complex conjugate as claimed in claim 1, and the particle size of the nanoparticles is 100 to 200 nm.

8. A method for preparing the nanoparticles according to claim 7, characterized in that: The method is as follows: 1 mg CuIr and 2 mg distearoyl phosphatidylethanolamine-polyethylene glycol are dissolved in 1 mL tetrahydrofuran respectively, added dropwise into 10 mL water, stirred and evaporated at room temperature for 24 hours, and then dialyzed using a 2000 molecular weight dialysis membrane to obtain CuIr NPs with uniform particle size and stability.

9. Use of the bimetallic iridium complex conjugate according to claim 1 or the nanoparticles according to claim 7 as phototherapy materials.

10. The use according to claim 9, wherein the phototherapy material is a photosensitive initiator.

11. Use of the bimetallic iridium complex conjugate according to claim 1 or the nanoparticles according to claim 7 in the preparation of thrombolytic drugs.

12. The use according to claim 11, wherein the thrombolytic drug is a drug for treating thrombosis.

Citation Information

Patent Citations

  • Preparation method and application of metal-porphyrin-based metal organic hexahedron supramolecular cage complex

    CN112851684A

  • Preparation method and application of copper porphyrin metal organic cage with photo-catalytic oxidation primary amine coupling performance

    CN116731024A

  • Porphyrin-based cubic metal-organic cage complex and application of porphyrin-based cubic metal-organic cage complex in photodynamic therapy

    CN116854698A

  • Copper-iron bimetal organic framework drug carrier, preparation method thereof and anti-cancer drug

    CN118271635A

Cited By

  • Bimetallic iridium complex conjugate, nanoparticle, preparation method and application in ischemic stroke

    CN119708073A

  • A bimetallic iridium complex conjugate, nanoparticles, preparation method and application in ischemic stroke

    CN119708073B